

Biologics - November 2023

Date	Company	Cluster	About	Investment (\$Millions USD)	Financing Type	Investors / Information
11-27	Arvinas	Connecticut	Arvinas is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. Arvinas uses its proprietary PROTAC® Discovery Engine platform to engineer proteolysis targeting chimeras, or PROTAC targeted protein degraders, that are designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins.	\$350.00	Post IPO Equity	This week's transaction involves the sale of 12,963,542 common stock shares at \$21.36 per share, accompanied by pre-funded warrants for an additional 3,422,380 shares at a price of \$21.359, as disclosed in a Nov. 27 filing with the U.S. Securities and Exchange Commission. The private placement was co-led by EcoR1 Capital and entities managed by RTW Investments LP, featuring participation from Adage Capital Partners LP, ArrowMark Partners, Avidity Partners, BB Biotech, Boxer Capital, Citadel Global Equities, Great Point Partners, LLC, Nextech Invest Ltd, RA Capital Management, and Surveyor Capital.
11-15	Mural Oncology	Europe	Mural Oncology is a protein engineering platform to reimagine cytokine-based immunotherapies for the treatment of cancer.	\$275.00	Venture	Sofinnova Partners, F-Prime Capital, Digitalis Ventures and Cambridge Innovation Capital.
11-13	VectorY	Europe	VectorY is an integrated gene therapy company focused on development of therapeutics for CNS, somatic disorders and muscle diseases.	\$138.00	Series A	co-led by EQT Life Sciences and the Forbion Growth Opportunities Fund. MRL Ventures Fund, a corporate venture arm of Merck & Co., Inc., Rahway, NJ USA, Insight Partners, ALS Investment Fund, Forbion Ventures, BioGeneration Ventures (BGV) and another known investor.
11-14	MBrace Therapeutics	San Diego	MBrace Therapeutics is a privately held biopharmaceutical business.	\$85.00	Series B	TPG Life Sciences Innovations (TPG LSI), and its multi-sector impact strategy, The Rise Fund. New investors Avidity Partners and Cowen Healthcare Investments joined the round, along with continued support from existing Series A investors Venrock and Alta Partners.
11-14	Nouscom	Europe	Nouscom are a biotech company working to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells.	\$72.00	Post IPO Equity	M Ventures, Andera Partners, bpifrance, Xgen, Revelation Partners, Panakes Partners, M Ventures, Indaco Venture Partners, EQT Life Science, 5Am Ventures, Versant Ventures
11-14	SAB Therapeutic	South Dakota		\$67.10	Venture	Sessa Capital, BVF Partners, RTW Investments, Marshall Wace, ATW
11-08	Forward Therapeutics	Florida	Forward Therapeutics is a biopharma company targeting treatment of chronic inflammatory disorders.	\$50.00	Series A	BVF Partners, RA Capital Management, Orbimed
11-21	ORYZON	Europe	ORYZON is a public clinical stage biopharmaceutical company and the European leader in the development of epigenetics-based therapeutics, with a strong focus on personalized medicine approaches to CNS disorders and oncology.	\$49.25	Debt	Initial execution of €8 million in two tranches of €4 million each, plus optional additional tranches of up to €5 million each to be executed in the future, at Oryzon's request, subject to customary conditions
11-30	Arrivo BioVentures	North Carolina	Arrivo BioVentures is a pharmaceutical development company which focuses on identifying biologics and molecules to improve patient care.	\$45.30	Series B	Orlando Health Ventures, Solas Ventures, Rex Health
11-28	Aro Biotherapeutics	Philadelphia	Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.	\$41.50	Series B	The round was led by Cowen Healthcare Investments, with participation from existing investors from Aro's Series A financing round in 2020, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Northpond Ventures, Healthcap and BVF Partners
11-13	Acumen Pharmaceuticals	Virginia	clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers ("AβOs") for the treatment of Alzheimer's disease ("AD")	\$30.00	Debt	
11-02	Memo Therapeutics	Europe	Memo Therapeutics is an innovator in the field of antibody discovery and immune repertoire analysis.	\$28.60	Series C	Pureos Bioventures (lead), Vesalius Biocapital Partners, Verve Ventures, Swisscanto, Schrodgers Capital, Redalpine, GF Group, Fresenius Medical Care, Adjuvant Capital

Date	Company	Cluster	About	Investment (\$Millions USD)	Financing Type	Investors / Information
11-13	ViaNautis	Europe - UK	ViaNautis is at the forefront of developing novel medications capable of crossing biological barriers.	\$24.80	Series A	UCB Ventures, BGF Ventures, 4Bio Capital (Leads) Origin Capital, O2h Ventures, Meltwind Advisory, Eli Lilly, Cystic Fibrosis Foundation,
11-30	Tharimmune	New Jersey	Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for rare, inflammatory, and oncologic diseases. The Company has acquired an exclusive worldwide license for a clinical-stage asset, known to suppress chronic, debilitating pruritis or "uncontrollable itching" in PBC, a rare and orphan liver disease with no known cure. The Company's early-stage immuno-oncology pipeline includes novel multi-specific antibodies targeting unique epitopes with novel mechanisms of action against well-known, validated targets in multiple solid tumors.	\$11.00	Post IPO Equity	Public Offering
11-24	Gain Therapeutics	Washington D.C. / Baltimore	Gain Therapeutics is a biotech company developing pharmacological chaperones drugs designed to treat rare metabolic disorders.	\$10.10	Post IPO Equity	secondary issue of common stock and warrants, partly via a public offering as well as private placement, approximately amounting to \$9.4 million. With regard to the public issue, Gain Therapeutics will issue \$2.2 million shares at a price of \$2.005 each. Per the terms of the offer, every 2 shares of common stock will be accompanied by a warrant.
11-10	Fortress Biotech	New York	Fortress Biotech is a biopharmaceutical company that focuses on acquiring, developing, and commercializing therapeutic products.	\$10.00	Post IPO Equity	
11-22	PaxMedica	New York	PaxMedica, Inc. is a forward-looking clinical-stage biopharmaceutical firm specializing in cutting-edge anti-purinergic drug therapies (APT) aimed at addressing a range of challenging neurologic disorders, including Autism Spectrum Disorder (ASD) and Human African Trypanosomiasis (HAT).	\$7.00	Post IPO Equity	
11-07	Amyl Therapeutics	Europe	Amyl Therapeutics is a preclinical stage biotechnology company.	\$6.60	Grant	
11-28	Portage Biotech	Connecticut	Portage Biotech is a pharmaceutical company that identifies and develops best-in-class or first-in-class early-to-mid stage products.	\$6.00	Post IPO Equity	
11-07	Amyl Therapeutics	Europe	Amyl Therapeutics is a preclinical stage biotechnology company.	\$5.70	Series A	Meusinvest and Mérieux Equity Partners
11-20	CEL-SCI Corporation	Virginia	a Phase 3 cancer immunotherapy company	\$5.00	Post IPO Equity	
11-02	Avenue Therapeutics	Miami	specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases	\$5.00	Post IPO Equity	
11-14	HemoShear Therapeutic	Virginia	HemoShear Therapeutics develops new treatments for patients with rare metabolic disorders.	\$3.50	Debt	
11-20	Cantai Therapeutics	Boston	Cantai Therapeutics operates as a developer of drug candidates.	\$0.80	Seed	Agent Capital, Tellus BioVentures, 82VS
11-17	SynaptixBio	Europe - UK	SynaptixBio is a biotechnology research company that develops lifesaving therapies for severe leukodystrophies.	\$0.62	Grant	Innovate UK